Dr. Bekaii-Saab on Expanding Landscape in CRC

Tanios Bekaii-Saab, MD
Published: Wednesday, Mar 01, 2017



Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the expanding treatment landscape of colorectal cancer (CRC).

The armamentarium in CRC is expanding; moreover, agents across multiple lines of therapy are becoming available for patients and, overall, improving their survival, Bekaii-Saab explains. It is very important to understand sequencing of therapies, he adds. This is a major question currently among the CRC community.

In the second-line setting, there are 2 agents available: regorafenib (Stivarga) and TAS-102. The optimal sequence of these agents in the second-line setting is still unknown, he adds.


Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the expanding treatment landscape of colorectal cancer (CRC).

The armamentarium in CRC is expanding; moreover, agents across multiple lines of therapy are becoming available for patients and, overall, improving their survival, Bekaii-Saab explains. It is very important to understand sequencing of therapies, he adds. This is a major question currently among the CRC community.

In the second-line setting, there are 2 agents available: regorafenib (Stivarga) and TAS-102. The optimal sequence of these agents in the second-line setting is still unknown, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x